Related Experiment Video
Updated: Jul 15, 2026
Blood Circuit Reconstruction in an Abdominal Mouse Heart Transplantation Model
Published on: June 3, 2021
Heart transplantation: a magnified model of heart-brain interactions
Mohamad H Yamani1, Randall C Starling
1Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. yamanim@ccf.org
Insights
The human heart transplant model reveals an active heart-brain connection. This research explores potential therapies, like mTOR inhibitors, to combat cardiac allograft vasculopathy and improve transplant survival.
Area of Science:
- Cardiovascular Science
- Neurocardiology
- Transplantation Immunology
Background:
- Coronary allograft vasculopathy (CAV) is a major cause of cardiac transplant failure.
- The heart-brain axis plays an active role in cardiovascular health and disease.
- Understanding the pathophysiology of CAV is crucial for improving long-term transplant recipient survival.
Purpose of the Study:
- To investigate the heart-brain link in the context of cardiac transplantation.
- To explore potential therapeutic targets for attenuating coronary allograft vasculopathy.
- To gain insights into the pathophysiology of hypertension and vascular disease.
Main Methods:
- Utilized a human heart transplant model to study heart-brain interactions.
- Reviewed existing literature on mTOR inhibitors and their potential in CAV.
- Discussed other potential targeted therapies for CAV.
Main Results:
- The heart-brain link is an active process demonstrable at the tissue level in heart transplant recipients.
- mTOR inhibitors show promise in attenuating CAV.
- Glycoprotein IIb/IIIa inhibitors, tissue metalloproteinase inhibitors, and angiotensin receptor blockers may also be beneficial.
Conclusions:
- Cardiac transplantation magnifies heart-brain interactions, offering a unique model to study cardiovascular pathophysiology.
- Targeted therapies are needed to combat CAV and improve long-term cardiac allograft survival.
- Further research is required to confirm the efficacy of various targeted therapies in clinical trials.
Abstract:
The human heart transplant model unmasks the heart-brain link as an active process that is clinically demonstrated and confirmed at the tissue level. Further studies are needed to elucidate the relative contribution of each of these isolated observations to the pathogenesis of coronary allograft vasculopathy, which remains enigmatic. Recent studies have suggested that mTOR inhibitors may have the ability to attenuate this lethal process that limits the long-term survival of cardiac transplant recipients. The observations we have discussed here suggest that other targeted therapies, including glycoprotein IIb/IIIa inhibitors, tissue metalloproteinase inhibitors, and angiotensin receptor blockers, may facilitate the attenuation of cardiac transplant vasculopathy, but clinical trials are difficult to conduct in this relatively small population of patients. These observations may shed insight, however, into the pathophysiology of hypertension and its impact on the vascular system, as cardiac transplantation provides a setting in which heart-brain interactions are magnified and the pathophysiology occurs over years rather than decades.
